


REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of

Application Number

67/155943

Filed

2-16-88

Art Unit

Examiner

Paper No. 46

Assistant Commissioner for Patents
Washington, DC 20231

1. ☒ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☒ (A) referred to in:

United States Patent Application Publication No. _____, page _____, line _____,

United States Patent Number 5284931, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Henry Dunc
Signature

3-24-03
Date

HENRY DUNC
Typed or printed name

FOR PTO USE ONLY

Approved by: _____

(initials)

Unit: _____



US005284931A

United States Patent [19]

Springer et al.

[11] Patent Number: **5,284,931**[45] Date of Patent: **Feb. 8, 1994****[54] INTERCELLULAR ADHESION
MOLECULES, AND THEIR BINDING
LIGANDS****[75] Inventors:** Timothy A. Springer, Newton, Mass.;
Robert Rothlein; Steven D. Marlin,
both of Danbury, Conn.; Michael L.
Dustin, University City, Mo.**[73] Assignee:** Dana Farber Cancer Institute,
Boston, Mass.**[21] Appl. No.:** 515,478**[22] Filed:** Apr. 27, 1990**Related U.S. Application Data****[63]** Continuation-in-part of Ser. No. 456,647, Dec. 22,
1989, which is a continuation-in-part of Ser. No.
45,963, May 4, 1987, which is a continuation-in-part of
Ser. No. 115,798, Nov. 2, 1987, which is a contin-
uation-in-part of Ser. No. 155,943, Feb. 16, 1988, which is
a continuation-in-part of Ser. No. 189,813, May 3, 1988,
which is a continuation-in-part of Ser. No. 250,446,
Sep. 28, 1988, which is a continuation-in-part of Ser.
No. 324,481, Mar. 16, 1989, which is a continuation-in-
part of Ser. No. 373,882, Jun. 30, 1989, which is a
continuation-in-part of Ser. No. 456,647, Dec. 22, 1989.**[51] Int. Cl.³** A61K 39/395**[52] U.S. Cl.** 424/85.8; 530/388.22;
530/395; 530/808; 530/868; 514/8**[58] Field of Search** 424/85.8, 85.91;
530/387, 389, 808, 388.22**[56] References Cited****PUBLICATIONS**

Cunningham C; et al., *TIBTECH* 10, Apr., 1992. "Anti-
body engineering—how to be human."
Dantel, J., et al., *Curr. Opin. Immunol.* 3:740-747
(1991), "Use of Monoclonal antibodies in human trans-
plantation,"
Flavin, T., et al., *Transpl. Proc.* 23(1):533-534 (Feb.
1991) "Monoclonal antibodies against intercellular ad-
hesion molecule 1 prolong carioige allograft survival in
CY momolgus monkeys."
Gibbs, W. W., *Scientific American* (Jul. 1993), "Try,
try again," pp. 101-103.

Hams, W. J., et al. *Tibtech* 11 (Feb. 1993), pp. 42-44.
"Therapeutic antibodies—the coming of age."
Haug, C. E., et al., *Transplantation* 55:766-773, (Apr.
1993), "A Phase I trial of immunosuppression with
anti-, cam-12 (CD54) m Ab in renal allograft recipi-
ents."

Ortho Multicenter Transplant Study Group, *New Engl.
J. Med.* 313:337-341 (Aug. 8, 1985).

Physician's Desk Reference (1993), pp. 1702-1703. "Or-
thoclone OKT3".

Marlin, S. D. et al. 1987. *Cell* 51: 813-819. "Purified
Intercellular Adhesion Molecule-1 . . ."

Rothlein, R. et al. 1986. *J. Immunol.* 137:1270-1274. "A
Human Intercellular Adhesion Molecule (ICAM-1) . . ."

Dustin, M. L. et al. 1986. *J. Immunol.* 137(1):245 "In-
duction by IL1 and Interferon- γ . . ."

Cosimi et al., *J. Immunol.* 144(12):4604-4612 (1990).

Flavin et al., *Transplant. Proc.* 23(1):553-534 (1991).

Tolkoff-Rubin et al., *J. Amer. Soc. Nephrology* 2(3):820
No. 2P (1991).

Kavanaugh et al., *56th Meeting of Amer. College of
Rheumatology*, Oct. 13-15, Atlanta, Ga. (1992).

Boyd et al., *Proc. Natl. Acad. Sci. USA* 85:3095-3099
(1988).

(List continued on next page.)

Primary Examiner—Christine M. Nucker**Assistant Examiner**—Thomas Cunningham**Attorney, Agent, or Firm**—Sterne, Kessler, Goldstein &
Fox**[57]****ABSTRACT**

Pharmaceutical compositions comprising antibodies to
intercellular adhesion molecule-1 (ICAM-1 or CD54)
are useful in methods of decreasing the severity of in-
flammation associated with the adhesion of leukocytes
to cells bearing ICAM-1. Treatment with anti-ICAM-1
antibodies reduced the severity of inflammation associ-
ated with acute organ or tissue rejection and prolonged
allograft survival time. Such compositions may option-
ally contain other immunosuppressive agents.

11 Claims, 25 Drawing Sheets